We hypothesized that treatment with an inhibitor of tau self-association would affect the entire aggregation process, leading to the reduction of self-associated tau and the increasingly larger aggregates that accumulate in AD and related tauopathies. This evidence concerns the gene MAPT and Alzheimer disease.